Literature DB >> 17955278

Serum hyaluronic acid levels in patients with ankylosing spondylitis.

Mehmet Tuncay Duruöz1, Yasemin Turan, Lale Cerrahoglu, Banu Isbilen.   

Abstract

Our aim in this study was to investigate serum hyaluronic acid (HA) levels and the relationship between clinical parameters in ankylosing spondylitis (AS). Approximately 30 patients with AS and 30 healthy individuals were recruited in this study consecutively. Cross-sectional study was planned, and demographic, clinical, functional, radiological, and laboratory data of patients were evaluated. Disease activity, functional status, and quality of life were assessed, respectively, with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Short-Form 36 (SF-36). Mander Enthesis Index (MEI) was used for evaluation of enthesis involvement. We examined serum concentrations of HA (ng/ml) in patients with AS and controls. The mean ages of patients and control group were 38.3 (SD=10.8) and 42.7 (SD=10.6) years, respectively. The mean of serum HA levels in AS patients was 40.4 (SD=34.8) ng/ml and in controls was 24.9 (SD=20.2). There was significant difference of HA levels between two groups (p=0.04). Furthermore, there was a significant correlation between HA level and distance of hand-floor (r=0.444, p=0.014), modified lumbar Schober's (r= -0.413, p=0.023), distance of chin to chest (r=0.436, p=0.016), right sacroiliit grade (r=0.601, p<0.001), left sacroiliit grade (r=0.610, p<0.001), C reactive protein level (r=0.404, p=0.027), albumin (r= -0.464, p=0.010), C3 (p=0.449, p=0.013), and IgA levels (r=0.369, p=0.045). However, there was no significant correlation between HA levels with MEI, BASFI, BASDAI, and SF-36 (p >or= 0.05). Serum HA level was significantly higher in AS patients than controls. However, there was no significant correlation between serum HA level and disease-specific measures as BASFI and BASDAI; it had significant relation with spinal mobility limitation, sacroiliitis, and laboratory parameters related with acute inflammation. The serum HA level may be a potential biomarker of axial inflammation and disease severity in AS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17955278     DOI: 10.1007/s10067-007-0757-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

Review 1.  Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases.

Authors:  P Garnero; J C Rousseau; P D Delmas
Journal:  Arthritis Rheum       Date:  2000-05

2.  Different effects of thyroid disease on serum levels of procollagen III N-peptide and hyaluronic acid.

Authors:  J Faber; K Hørslev-Petersen; H Perrild; I Lorenzen
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

3.  Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy.

Authors:  A Engström-Laurent; R Hällgren
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

4.  Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

Authors:  K Hørslev-Petersen; K D Bentsen; A Engström-Laurent; P Junker; P Halberg; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

5.  Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity.

Authors:  W Emlen; J Niebur; G Flanders; J Rutledge
Journal:  J Rheumatol       Date:  1996-06       Impact factor: 4.666

6.  Serum levels of hyaluronic acid in patients with psoriatic arthritis.

Authors:  O Elkayam; I Yaron; I Shirazi; M Yaron; D Caspi
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

7.  Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis.

Authors:  R J François; D L Gardner; E J Degrave; E G Bywaters
Journal:  Arthritis Rheum       Date:  2000-09

8.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

9.  Circulating hyaluronate. A potential marker of altered metabolism of the connective tissue in uremia.

Authors:  R Hällgren; A Engström-Laurent; U Nisbeth
Journal:  Nephron       Date:  1987       Impact factor: 2.847

10.  The catabolic fate of hyaluronic acid.

Authors:  T C Laurent; I M Dahl; L B Dahl; A Engström-Laurent; S Eriksson; J R Fraser; K A Granath; C Laurent; U B Laurent; K Lilja
Journal:  Connect Tissue Res       Date:  1986       Impact factor: 3.417

View more
  4 in total

1.  Toll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activity.

Authors:  T W Kragstrup; T Andersen; C Holm; B Schiøttz-Christensen; A G Jurik; M Hvid; B Deleuran
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

2.  Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis.

Authors:  T W Kragstrup; M N Andersen; B Schiøttz-Christensen; A G Jurik; M Hvid; B Deleuran
Journal:  Clin Exp Immunol       Date:  2017-05-02       Impact factor: 4.330

Review 3.  The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.

Authors:  Tue W Kragstrup; Thomas Andersen; Line D Heftdal; Malene Hvid; Jens Gerwien; Pallavur Sivakumar; Peter C Taylor; Ladislav Senolt; Bent Deleuran
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

4.  Fragmented hyaluronan has no alarmin function assessed in arthritis synovial fibroblast and chondrocyte cultures.

Authors:  Mia Olsson; Lisa Bremer; Cecilia Aulin; Helena Erlandsson Harris
Journal:  Innate Immun       Date:  2018-02       Impact factor: 2.680

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.